Altin Ekin Meryem
Department of Ophthalmology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
Cutan Ocul Toxicol. 2024 Dec;43(4):278-286. doi: 10.1080/15569527.2024.2402402. Epub 2024 Sep 17.
To determine whether botulinum toxin is effective and safe for the treatment of epiphora, and to compare its utility in functional versus non-functional epiphora using both qualitative and quantitative methods.
Patients were divided into two groups (functional and non-functional epiphora) according to the presence of lacrimal drainage obstruction. All patients were injected with 2.5 units of botulinum toxin into the palpebral lobe of the lacrimal gland, and improvement in epiphora and quality of life were assessed both objectively and subjectively using Schirmer's I test, indoor and outdoor Munk scores, TEARS score, watery eye quality of life score, and tear meniscus measurements at pre-injection, and 1, 3, and 6 months post-injection. Functional and non-functional epiphora groups were compared.
Botulinum toxin was injected into 72 lacrimal glands of 65 patients with functional and non-functional epiphora. In both the functional and non-functional epiphora groups, the mean Schirmer's I test value, indoor and outdoor Munk scores, TEARS score, watery eye quality of life score, tear meniscus height, depth, and area values improved significantly at 1, 3, and 6 months after injection compared with pre-injection values ( < 0.05). There were statistically significant differences in mean Schirmer's I test, tear meniscus height, depth, and area values between the functional and non-functional epiphora groups at 1, 3, and 6 months after botulinum toxin injection ( < 0.05). In the functional epiphora group, a greater proportion of patients reported improvement than in the non-functional group. All complications were minor and resolved within 2 weeks after the injection.
Botulinum toxin injection into the lacrimal glands of patients with functional and non-functional epiphora was a simple, effective, and safe treatment. In addition to qualitative methods, quantitative methods, such as tear meniscus measurement, provided direct evidence that symptomatic improvement occurred more in those with functional versus non-functional epiphora after botulinum toxin injection.
确定肉毒杆菌毒素治疗泪溢是否有效和安全,并使用定性和定量方法比较其在功能性泪溢与非功能性泪溢中的效用。
根据泪道阻塞情况将患者分为两组(功能性泪溢和非功能性泪溢)。所有患者均在泪腺睑叶注射2.5单位肉毒杆菌毒素,并在注射前、注射后1、3和6个月使用Schirmer I试验、室内和室外蒙克评分、TEARS评分、流泪生活质量评分以及泪液弯月面测量,从客观和主观两方面评估泪溢改善情况及生活质量。对功能性和非功能性泪溢组进行比较。
对65例功能性和非功能性泪溢患者的72个泪腺注射了肉毒杆菌毒素。在功能性和非功能性泪溢组中,与注射前相比,注射后1、3和6个月时Schirmer I试验平均值、室内和室外蒙克评分、TEARS评分、流泪生活质量评分、泪液弯月面高度、深度和面积值均有显著改善(P<0.05)。肉毒杆菌毒素注射后1、3和6个月,功能性和非功能性泪溢组在Schirmer I试验平均值、泪液弯月面高度、深度和面积值方面存在统计学显著差异(P<0.05)。在功能性泪溢组中,报告症状改善的患者比例高于非功能性组。所有并发症均较轻微,在注射后2周内消退。
对功能性和非功能性泪溢患者的泪腺注射肉毒杆菌毒素是一种简单、有效且安全的治疗方法。除定性方法外,泪液弯月面测量等定量方法提供了直接证据,表明肉毒杆菌毒素注射后,功能性泪溢患者的症状改善比非功能性泪溢患者更明显。